X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/30/2872119/0/en/Tenax-Therapeutics-Announces-New-U-S-Patent-Covering-the-Use-of-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-HFpEF.html
https://www.globenewswire.com/news-release/2024/04/09/2859987/0/en/Tenax-Therapeutics-to-Host-KOL-Event-LEVEL-Setting-the-Scientific-Rationale-for-Levosimendan-as-a-Potential-First-Treatment-for-PH-HFpEF-and-the-Ongoing-Phase-3-LEVEL-Study.html
https://www.globenewswire.com/news-release/2024/03/28/2854007/0/en/Tenax-Therapeutics-Provides-Business-and-Clinical-Development-Updates-with-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/12/2844526/0/en/Tenax-Therapeutics-to-Present-at-the-36th-Annual-Roth-Conference.html
https://feeds.issuerdirect.com/news-release.html?newsid=6432598367320275
https://www.globenewswire.com//news-release/2024/02/20/2831850/0/en/Tenax-Therapeutics-Announces-Global-License-Amendment-that-Significantly-Expands-Rights-to-Levosimendan.html
https://www.globenewswire.com//news-release/2024/02/08/2826006/0/en/Tenax-Therapeutics-Announces-Pricing-of-Approximately-9-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/02/08/2825648/0/en/Tenax-Therapeutics-Enrolls-First-Patient-in-Phase-3-LEVEL-Study-Evaluating-TNX-103-Oral-Levosimendan-for-the-Treatment-of-Pulmonary-Hypertension-in-Heart-Failure-with-Preserved-Eje.html
https://www.globenewswire.com//news-release/2024/02/06/2824335/0/en/Tenax-Therapeutics-Announces-USPTO-Grants-Notice-of-Allowance-for-U-S-Patent-Application-Significantly-Broadening-IP-Protection-for-Use-of-Levosimendan-in-Pulmonary-Hypertension-wi.html
https://www.globenewswire.com/news-release/2023/12/29/2802054/0/en/Tenax-Therapeutics-Announces-Reverse-Stock-Split.html
Market Place
Share 
